Limit Allogeneic Blood Use with Routine Re-use of Patient's Own Blood: A Prospective, Randomized, Controlled Trial in Total Hip Surgery

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Thomassen, Bregje J W ^a   Pilot, Peter ^b   Scholtes, Vanessa A B ^c   Grohs, Josef G ^d   Holen, Ketil ^e   Bisbe, Elvira ^f   Poolman, Rudolf W ^c  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f HOSPITAL DE L ESPERANÇA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ALLOGENEIC BLOOD TRANSFUSION; ARTICLE; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINGLE BLIND PROCEDURE; TOTAL HIP PROSTHESIS;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84866422717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044503     Document Type: Article

References (33)

1. Grzelak I, Zaleska M, Olszewski WL, (1998) Blood transfusions downregulate hematopoiesis and subsequently downregulate the immune response. Transfusion 38: 1104-1114.
2. Tartter PI, (1995) Immunologic effects of blood transfusion. Immunol Invest 24: 277-288.
3. Innerhofer P, Klingler A, Klimmer C, Fries D, Nussbaumer W, (2005) Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion 45: 103-110.
4. Duffy G, Neal KR, (1996) Differences in post-operative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomized and nonrandomized studies. Transfus Med 6: 325-328.
5. Dodd RY, (2005) Current estimates of transfusion safety worldwide. Dev Biol (Basel) 120: 3-10.
6. Wylie BR, (1993) Transfusion transmitted infection: viral and exotic diseases. Anaesth Intensive Care 21: 24-30.
7. Glance LG, Dick AW, Mukamel DB, Fleming FJ, Zollo RA, et al. (2011) Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology 114: 283-292.
8. Spahn DR, Moch H, Hofmann A, Isbister JP, (2008) Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology 109: 951-953.
9. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, et al. (2010) Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 50: 753-765.
10. Thoms RJ, Marwin SE, (2009) The role of fibrin sealants in orthopaedic surgery. J Am Acad Orthop Surg 17.
11. Sukeik M, Alshryda S, Haddad FS, Mason JM, (2011) Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 93: 39-46.
12. Weber EW, Slappendel R, Hemon Y, Mahler S, Dalen T, et al. (2005) Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 22: 249-257.
13. Moonen AF, Knoors NT, van Os JJ, Verburg AD, Pilot P, (2007) Retransfusion of filtered shed blood in primary total hip and knee arthroplasty: a prospective randomized clinical trial. Transfusion 47: 379-384.
14. Munoz M, Ariza D, Garceran MJ, Gomez A, Campos A, (2005) Benefits of postoperative shed blood reinfusion in patients undergoing unilateral total knee replacement. Arch Orthop Trauma Surg 125: 385-389.
15. Munoz M, Garcia-Erce JA, Villar I, Thomas D, (2009) Blood conservation strategies in major orthopaedic surgery: efficacy, safety and European regulations. Vox Sang 96: 1-13.
16. Garvin KL, Feschuk CA, Sekundiak TD, Lyden ER, (2005) Blood salvage and allogenic transfusion needs in revision hip arthroplasty. Clin Orthop Relat Res 441: 205-209.
17. Carless PA, Henry DA, Moxey AJ, O'Connell D, Brown T, et al. (2010) Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev CD001888.
18. Munoz M, Cobos A, Campos A, Ariza D, Munoz E, et al. (2006) Post-operative unwashed shed blood transfusion does not modify the cellular immune response to surgery for total knee replacement. Acta Anaesthesiol Scand 50: 443-450.
19. Andersson I, Tylman M, Bengtson JP, Bengtsson A, (2001) Complement split products and pro-inflammatory cytokines in salvaged blood after hip and knee arthroplasty. Can J Anaesth 48: 251-255.
20. Kvarnstrom A, Schmidt A, Tylman M, Jacobsson M, Bengtsson A, (2008) Complement split products and proinflammatory cytokines in intraoperatively salvaged unwashed blood during hip replacement: comparison between heparin-coated and non-heparin-coated autotransfusion systems. Vox Sang 95: 33-38.
21. Stachura A, Krol R, Poplawski T, Michalik D, Pomianowski S, et al. (2011) Transfusion of intra-operative autologous whole blood: influence on complement activation and interleukin formation. Vox Sang 100: 239-246.
22. Hurle R, Poma R, Maffezzini M, Manzetti A, Piccinelli A, et al. (2004) A simple mathematical approach to calculate blood loss in radical prostatectomy. Urol Int 72: 135-139.
23. del Trujillo MM, Carrero A, Munoz M, (2008) The utility of the perioperative autologous transfusion system OrthoPAT in total hip replacement surgery: a prospective study. Arch Orthop Trauma Surg 128: 1031-1038.
24. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16: 199-208.
25. Brooks R, (1996) EuroQol: the current state of play. Health Policy 37: 53-72.
26. Grosvenor D, Goyal V, Goodman S, (2000) Efficacy of postoperative blood salvage following total hip arthroplasty in patients with and without deposited autologous units. J Bone Joint Surg Am 82-A: 951-954.
27. Strumper D, Weber EW, Gielen-Wijffels S, Van DR, Bulstra S, et al. (2004) Clinical efficacy of postoperative autologous transfusion of filtered shed blood in hip and knee arthroplasty. Transfusion 44: 1567-1571.
28. Weber EW, Slappendel R, Prins MH, van der Schaaf DB, Durieux ME, et al. (2005) Perioperative blood transfusions and delayed wound healing after hip replacement surgery: effects on duration of hospitalization. Anesth Analg 100: 1416-21.
29. Lachin JM, (1981) Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 2: 93-113.
30. Poolman RW, Struijs PA, Krips R, Sierevelt IN, Marti RK, et al. (2007) Reporting of outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter? J Bone Joint Surg Am 89: 550-558.
31. Boutron I, Tubach F, Giraudeau B, Ravaud P, (2004) Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol 57: 543-550.
32. Salido JA, Marin LA, Gomez LA, Zorrilla P, Martinez C, (2002) Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg Am 84-A: 216-220.
33. Sharma R, Farrokhyar F, McKnight LL, Bhandari M, Poolman RW, et al. (2011) Quality of assessment of randomized controlled trials in blood conservation after joint arthroplasty. J Arthroplasty 26: 909-913.